Tekmira Pharmaceuticals Corp  

(Public, NASDAQ:TKMR)   Watch this stock  
Find more results for TKMR
11.63
-0.08 (-0.68%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.50 - 11.96
52 week 8.86 - 29.93
Open 11.50
Vol / Avg. 307,197.00/761,592.00
Mkt cap 630.42M
P/E     -
Div/yield     -
EPS -1.34
Shares 54.21M
Beta 0.46
Inst. own 67%
Aug 11, 2015
Q2 2015 Tekmira Pharmaceuticals Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 9, 2015
Tekmira Pharmaceuticals Corp Annual Shareholders Meeting - 5:00PM EDT - Add to calendar
Jun 24, 2015
Tekmira Pharmaceuticals Corp at JMP Securities Life Sciences Conference
Jun 2, 2015
Tekmira Pharmaceuticals Corp at Jefferies Global Healthcare Conference
May 7, 2015
Tekmira Pharmaceuticals Corp at Deutsche Bank Health Care Conference
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Call - Webcast
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -256.07% -259.73%
Operating margin -384.58% -223.59%
EBITD margin - -216.97%
Return on average assets -10.62% -40.90%
Return on average equity -14.11% -52.76%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Pky
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Age: 29
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Patrick Higgins Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 58
Bio & Compensation  - Reuters
Adam D. Cutler Senior Vice President - Corporate Affairs
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Michael J. Sofia Ph.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Bruce Dorsey Vice President - Chemistry
Bio & Compensation  - Reuters
Rene Cornelis Rijnbrand Vice President - Biology
Bio & Compensation  - Reuters